A Promotion and Implementation Project of HIV Pre-Exposure Prophylaxis Among High Risk Population

Sponsor
University of Chicago (Other)
Overall Status
Recruiting
CT.gov ID
NCT04754139
Collaborator
Gilead Sciences (Industry), Guangzhou 8th People's Hospital (Other), Social Entrepreneurship to Spur Health (SESH) (Other), Wuhan University (Other)
3,200
2
1
25.2
1600
63.4

Study Details

Study Description

Brief Summary

This study aims to use a social media mini-application-enabled intervention to successfully promote the initiation and persistence of pre-exposure prophylaxis (PrEP) among at-risk people 18 years and above (including men who have sex with men (MSM), transgender women, sex workers, and other key populations) in Wuhan and Guangzhou, China.

Condition or Disease Intervention/Treatment Phase
  • Other: WeChat mobile mini-application
N/A

Detailed Description

The China National Medical Products Administration (NMPA) recently approved TDF/FTC (Truvada) for PrEP making it the first HIV prevention medicine available in China. While this is a significant step in addressing the country's rising rates of new HIV diagnoses, implementation and scale-up of this resource will be the next challenge.

3200 at-risk adults will be engaged by word of mouth and social media. Individuals will be asked to complete a survey of risk and PrEP interest, to download the study mobile mini-application onto their cell phone, and will be offered an HIV and syphilis screen. One thousand two hundred of these subjects who are eligible and willing to start PrEP will be enrolled in the study. The first 700 participants enrolled in each site will complete an additional four-phased, WeChat-based adherence intervention through a stepped-wedge design, with each cluster starting at three-month intervals.

Enrolled participants will undergo baseline laboratory testing before brought to a collaborating hospital where an established physician will provide TDF/FTC and arrange follow-up. Rural and out-of-town enrollees may undergo testing at an outside lab. All subjects will be encouraged to keep using the mini-application for receiving constant health education and counseling support on HIV/STI prevention, PrEP initiation and/or adherence management. Subjects on PrEP will be contacted every three months over the course of two years to answer questions on adherence including number of missed pills and/or sex events not covered by on-demand PrEP, adverse effect, and utilization of the mini-application. 120 enrollees in Guangdong will additionally participate in a pill count adherence sub study that counts the number of unused pills at each clinical follow-up

A PrEP messaging open contest will be organized to assess the best images and videos to enhance PrEP adherence among those who start PrEP. New content will be developed using crowdsourcing and introduced into the mini-application at staggered times. The effect of this content will be evaluated through a stepped wedge approach nested within this single arm study.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
3200 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Health Services Research
Official Title:
A Promotion and Implementation Project of HIV Pre-Exposure Prophylaxis Among High Risk Population
Actual Study Start Date :
Sep 24, 2021
Anticipated Primary Completion Date :
Nov 1, 2023
Anticipated Study Completion Date :
Nov 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: WeChat mobile mini-application

WeChat mini-application will increase knowledge base about sexual health through interactive health education and counseling support on HIV/STI prevention as well as PrEP initiation and/or adherence management.

Other: WeChat mobile mini-application
Sexual health education and the role of PrEP

Outcome Measures

Primary Outcome Measures

  1. PrEP prescriptions [2 years]

    Number of PrEP prescriptions fulfilled in Wuhan and Guangzhou, China

Secondary Outcome Measures

  1. HIV Screenings [2 years]

    Number of HIV screenings performed

  2. Syphilis screenings [2 years]

    Number of syphilis screenings performed

  3. Retention [12 months]

    Number of subjects retained in PrEP care at 6 and 12 months

  4. Adherence [2 years]

    Number of subjects that self-report PrEP adherence

  5. New HIV infection [2 years]

    Number of new HIV infections reported in PrEP users

  6. New syphilis infection [2 years]

    Number of new syphilis infections reported in PrEP users

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Age 18+

  • Engaged in at-risk sex. At risk sex is defined as sex with >1 partner in the past 90 days, inconsistent condom use with vaginal or anal sex, ongoing sexual relationship with an HIV-positive partner, participation in commercial sex work, or any bacterial STI diagnosed or reported in the past 6 months.

Exclusion Criteria:
  • History renal dysfunction

  • Chronic hepatitis B (HBV) infection

  • HIV infection

  • Indication for HIV post-exposure prophylaxis

  • Signs and symptoms consistent with acute HIV infection

  • Under the age range of 18

Contacts and Locations

Locations

Site City State Country Postal Code
1 Guangzhou Eighth People's Hospital Guangzhou China
2 Zhongnan Hospital of Wuhan University Wuhan China

Sponsors and Collaborators

  • University of Chicago
  • Gilead Sciences
  • Guangzhou 8th People's Hospital
  • Social Entrepreneurship to Spur Health (SESH)
  • Wuhan University

Investigators

  • Principal Investigator: Aniruddha Hazra, MD, University of Chicago

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University of Chicago
ClinicalTrials.gov Identifier:
NCT04754139
Other Study ID Numbers:
  • IRB20-1388
First Posted:
Feb 15, 2021
Last Update Posted:
Mar 16, 2022
Last Verified:
Mar 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University of Chicago

Study Results

No Results Posted as of Mar 16, 2022